Results 21 to 30 of about 9,833 (206)
Journal of Diabetes Investigation, 2019 A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped.
Takatoshi Anno +6 more
doaj +1 more source
Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients [PDF]
Diabetes & Metabolism Journal, 2011 BackgroundThe present study investigated the efficacy and safety of vildagliptin-metformin treatment compared to those of glimepiride-metformin treatment for type 2 diabetes.MethodsIn a randomized, open-label, comparative study, 106 patients with type 2 ...
Hyun Jeong Jeon, Tae Keun Oh
doaj +1 more source
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]
, 2009 BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K +4 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2012 Objective: Addition of vildagliptin to ongoing insulin therapy may help in terms of overall glycemic control as well as reduction in dose of insulin and weight.
Paresh Ved, Samrat Shah
doaj +1 more source
Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA [PDF]
, 2014 Background: Cardiovascular disease, endothelial dysfunction, and oxidative stress are common complications among patients with type 2 diabetes (T2DM). in addition to the average blood glucose concentration, glycemic variability may be an important factor
Casali, Karina Rabello +3 more
core +2 more sources
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
The Influence of Excipients’ Chemical Nature on the Degradation of Metformin and Vildagliptin [PDF]
Kemija u IndustrijiThe influence of the chemical nature of excipients (magnesium stearate, povidone, microcrystalline cellulose, lactose, crospovidone, and talc) on the degradation of metformin and vildagliptin was tested by forced degradation, using acid hydrolysis, base ...
Amra Demirović +2 more
doaj +1 more source
pharma-kritik, 2008 Mit Vildagliptin steht - neben Sitagliptin - ein weiterer sogen. DPP-4-Hemmer zur Verfügung. Das Medikament senkt das HbA1c weniger stark als Metformin. Daten zu klinisch relevanten Endpunkten liegen noch keine vor.
openaire +1 more source
Evaluation of cardioprotective effects of the incritinmimetics exenatideand vildagliptin in the experiment [PDF]
, 2017 The results of experimental and clinical trials make it clear that incretin mimetics possess pleiotropic effects and demonstrate the value in terms of assessment of their potential opportunities as cardioprotectors.
Danilenko, L. M. +4 more
core +2 more sources
International Journal of Endocrinology, 2015 The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy.
Andrea Tura +5 more
doaj +1 more source